

Boglarka Gyurkocza

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3800213/publications.pdf>

Version: 2024-02-01

45
papers

3,177
citations

471509

17
h-index

276875

41
g-index

45
all docs

45
docs citations

45
times ranked

4707
citing authors

#	ARTICLE	IF	CITATIONS
1	Hematopoietic Cell Transplantation is Feasible in Patients with Prior COVID-19 Infection. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 55.e1-55.e5.	1.2	5
2	Outcomes of relapsed B-cell acute lymphoblastic leukemia after sequential treatment with blinatumomab and inotuzumab. <i>Blood Advances</i> , 2022, 6, 1432-1443.	5.2	13
3	Impact of omitting post-transplant minidose-methotrexate doses in allogeneic hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2022, 63, 1686-1693.	1.3	2
4	Disparities in speed to BMT consult and allograft in 279 adults with AML. <i>Journal of Clinical Oncology</i> , 2022, 40, 6523-6523.	1.6	0
5	Racial disparities in access to alternative donor allografts persist in the era of "donors for all". <i>Blood Advances</i> , 2022, 6, 5625-5629.	5.2	12
6	Geriatric syndromes in 2-year, progression-free survivors among older recipients of allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 289-292.	2.4	4
7	Cellular Therapy During COVID-19: Lessons Learned and Preparing for Subsequent Waves. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 438.e1-438.e6.	1.2	11
8	Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant. <i>Leukemia and Lymphoma</i> , 2021, 62, 3394-3401.	1.3	17
9	Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 771.e1-771.e10.	1.2	17
10	Fractionated Infusion of Hematopoietic Progenitor Cells Does Not Improve Neutrophil Recovery or Survival in Allograft Recipients. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 852.e1-852.e9.	1.2	0
11	Racial Disparities in Access to Alternative Donor Allografts Persist in the Era of "Donors for All". <i>Blood</i> , 2021, 138, 423-423.	1.4	1
12	Favorable long-term outcomes of hematopoietic stem cell transplantation for CMML with myeloablative conditioning, anti-thymocyte globulin, and CD34+ selected graft. <i>Bone Marrow Transplantation</i> , 2020, 55, 1632-1634.	2.4	0
13	Phase I/II multisite trial of optimally dosed clofarabine and low-dose TBI for hematopoietic cell transplantation in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2020, 95, 48-56.	4.1	5
14	High progression-free survival after intermediate intensity double unit cord blood transplantation in adults. <i>Blood Advances</i> , 2020, 4, 6064-6076.	5.2	29
15	Recent advances in allogeneic hematopoietic cell transplantation for acute myeloid leukemia. <i>Current Opinion in Hematology</i> , 2020, 27, 115-121.	2.5	9
16	Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. <i>New England Journal of Medicine</i> , 2020, 382, 822-834.	27.0	435
17	A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1195-1202.	2.0	40
18	Characteristics and Impact of Post-Transplant Interdisciplinary Palliative Care Consultation in Older Allogeneic Hematopoietic Cell Transplant Recipients. <i>Journal of Palliative Medicine</i> , 2020, 23, 1653-1657.	1.1	1

#	ARTICLE	IF	CITATIONS
19	Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. <i>Journal of Clinical Investigation</i> , 2020, 130, 733-747.	8.2	161
20	Clinical Outcomes of Acute Myeloid Leukemia Patients Bridged to Allogeneic Stem Cell Transplant By Venetoclax Combination Therapy. <i>Blood</i> , 2020, 136, 16-17.	1.4	0
21	Second allogeneic hematopoietic cell transplantation for relapse after first allografts. <i>Leukemia and Lymphoma</i> , 2019, 60, 1758-1766.	1.3	12
22	Immune Cytopenias after Ex Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1136-1141.	2.0	7
23	Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 956-963.	2.0	18
24	Impact of Toxicity on Survival for Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 142-149.	2.0	16
25	Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 133-141.	2.0	11
26	Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	258
27	Early Fluid Overload Is Associated with an Increased Risk of Nonrelapse Mortality after Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2517-2522.	2.0	13
28	Loss of Microbiota Diversity after Autologous Stem Cell Transplant Is Comparable to Injury in Allogeneic Stem Cell Transplant. <i>Blood</i> , 2018, 132, 608-608.	1.4	9
29	The Impact of Toxicities on First-Year Outcomes after Ex Vivo CD34+â€“Selected Allogeneic Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2004-2011.	2.0	11
30	Adoptive T-Cell Therapy with 3rd Party CMV-pp65-Specific CTLs for CMV Viremia and Disease Arising after Allogeneic Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2017, 130, 747-747.	1.4	6
31	Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. <i>Science Translational Medicine</i> , 2016, 8, 339ra71.	12.4	404
32	Selection of Unrelated Allogeneic Hematopoietic Cell Donors Based on KIR3DL1 Allotypes Is Feasible and Results in Improved Disease-Free Survival in Transplant Recipients with MDS and AML. <i>Blood</i> , 2016, 128, 990-990.	1.4	4
33	Prognostic Importance of Pretransplant Functional Capacity After Allogeneic Hematopoietic Cell Transplantation. <i>Oncologist</i> , 2015, 20, 1290-1297.	3.7	43
34	Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. <i>Blood</i> , 2014, 124, 344-353.	1.4	437
35	Treosulfan, Fludarabine, and 2-Gy Total Body Irradiation Followed by Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 549-555.	2.0	47
36	Allogeneic Hematopoietic Cell Transplantation following Minimal Intensity Conditioning: Predicting Acute Graft-versus-Host Disease and Graft-versus-Tumor Effects. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 792-798.	2.0	27

#	ARTICLE	IF	CITATIONS
37	Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2013, 31, 1530-1538.	1.6	197
38	Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. <i>Blood</i> , 2013, 122, 1813-1821.	1.4	325
39	Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. <i>Blood</i> , 2012, 120, 1398-1408.	1.4	148
40	Allogeneic hematopoietic cell transplantation for MDS: For whom, when and how?. <i>Blood Reviews</i> , 2012, 26, 247-254.	5.7	15
41	Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantation. <i>Cancer</i> , 2012, 118, 2411-2419.	4.1	27
42	Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 2859-2867.	1.6	191
43	Allogeneic hematopoietic cell transplantation: the state of the art. <i>Expert Review of Hematology</i> , 2010, 3, 285-299.	2.2	142
44	Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Low-Dose Total Body Irradiation after Rejection of First Allografts. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1314-1322.	2.0	29
45	Tolerance and chimerism ¹ . <i>Transplantation</i> , 2003, 75, 26S-31S.	1.0	18